Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 558,969
  • Shares Outstanding, K 26,047
  • Annual Sales, $ 14,800 K
  • Annual Income, $ -90,750 K
  • 60-Month Beta 1.56
  • Price/Sales 41.89
  • Price/Cash Flow N/A
  • Price/Book 3.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.01
  • Number of Estimates 4
  • High Estimate -0.94
  • Low Estimate -1.10
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +1.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.63 +84.52%
on 11/14/19
25.07 -14.40%
on 12/12/19
+7.43 (+52.96%)
since 11/13/19
3-Month
8.13 +163.96%
on 10/10/19
25.07 -14.40%
on 12/12/19
+10.11 (+89.07%)
since 09/13/19
52-Week
8.13 +163.96%
on 10/10/19
25.68 -16.43%
on 01/07/19
-1.29 (-5.67%)
since 12/13/18

Most Recent Stories

More News
Assembly Biosciences Announces Pricing of $125 Million Public Offering

Assembly Biosciences, Inc. (Nasdaq: ASMB) ("Assembly"), today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share. In addition,...

ASMB : 21.46 (-9.87%)
Assembly Biosciences Announces Proposed Public Offering of Common Stock

Assembly Biosciences, Inc. (Nasdaq: ASMB) ("Assembly"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering....

ASMB : 21.46 (-9.87%)
Assembly Biosciences Announces Plenary Lecture at HEP DART 2019

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 21.46 (-9.87%)
Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 21.46 (-9.87%)
Assembly Biosciences: 3Q Earnings Snapshot

CARMEL, Ind. (AP) _ Assembly Biosciences Inc. (ASMB) on Thursday reported a loss of $25 million in its third quarter.

ASMB : 21.46 (-9.87%)
Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 21.46 (-9.87%)
Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 21.46 (-9.87%)
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ASMB : 21.46 (-9.87%)
Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today...

ASMB : 21.46 (-9.87%)
Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?

Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.

HOLX : 53.15 (-0.08%)
ASMB : 21.46 (-9.87%)
HCA : 142.86 (-0.50%)
EYEN : 3.30 (-1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ASMB with:

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

2nd Resistance Point 25.69
1st Resistance Point 23.58
Last Price 21.46
1st Support Level 19.51
2nd Support Level 17.55

See More

52-Week High 25.68
Last Price 21.46
Fibonacci 61.8% 18.98
Fibonacci 50% 16.91
Fibonacci 38.2% 14.83
52-Week Low 8.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar